1. Home
  2. IGR vs KALV Comparison

IGR vs KALV Comparison

Compare IGR & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CBRE Global Real Estate Income Fund of Beneficial Interest

IGR

CBRE Global Real Estate Income Fund of Beneficial Interest

HOLD

Current Price

$4.54

Market Cap

645.2M

Sector

Finance

ML Signal

HOLD

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$16.85

Market Cap

757.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IGR
KALV
Founded
2004
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
645.2M
757.7M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
IGR
KALV
Price
$4.54
$16.85
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$30.00
AVG Volume (30 Days)
709.7K
747.7K
Earning Date
01-01-0001
04-13-2026
Dividend Yield
13.93%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$50,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
495.66
52 Week Low
$4.20
$9.83
52 Week High
$5.37
$19.00

Technical Indicators

Market Signals
Indicator
IGR
KALV
Relative Strength Index (RSI) 29.41 56.12
Support Level $4.49 $14.59
Resistance Level $5.04 $19.00
Average True Range (ATR) 0.08 0.92
MACD -0.05 0.15
Stochastic Oscillator 0.99 49.20

Price Performance

Historical Comparison
IGR
KALV

About IGR CBRE Global Real Estate Income Fund of Beneficial Interest

CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: